Rosen Law Firm Closes Investigation and Concludes There is No Basis for Securities Claims Against HTBX

NEW YORK--()--Rosen Law Firm announces that, following discussions with management and having gained a better understanding of the facts surrounding Heat Biologic’s (NASDAQ:HTBX) recent bladder cancer trial for Vesigenurtacel-L (HS-410), including the positive immunological data generated from this trial, it is closing its investigation of HTBX. Rosen attorney Phil Kim stated “We have concluded that there is no suggestion that management misrepresented the results of the clinical trial, and there is no basis for any securities claims.”

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com